Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluorouracil 5%{relative};  ;   - topical cream - 5% w/w - active: fluorouracil 5%{relative}     excipient: methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate propylene glycol purified water stearyl alcohol white soft paraffin - dp-fluorouracil is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms, keratoa canthoma; bowen's disease; superficial basal-cell carcinoma.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluorouracil, quantity: 500 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon, rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Estats Units - anglès - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil cream, 0.5% is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. fluorouracil may cause fetal harm when administered to a pregnant woman. fluorouracil is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. no adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. one birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil. animal reproduction studies have not been conducted with fluorouracil cream, 0.5%. fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when adm

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 500 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 5 g - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.